article thumbnail

Get to Know Alys Pharmaceuticals, Inc.

The Dermatology Digest

Alys Pharmaceuticals, Inc. Alys combines six asset-centric Medicxi companies including Al Aldena Therapeutics, Graegis Pharmaceuticals, Granular Therapeutics, Klirna Biotech, Nira Biosciences and Vimela Therapeutics. ” The post Get to Know Alys Pharmaceuticals, Inc. appeared first on The Dermatology Digest.

article thumbnail

Case 2: Female, 15 Years Old

Dermatology Times

Dr Bhutani presents the case of a 15-year-old female with long standing atopic dermatitis and discusses the importance of balancing parental preferences for "natural" agents with effective pharmaceutical options.

article thumbnail

Label Update: FDA Green Lights Dupilumab for AD Patients With Moderate-to-Severe Hand and Foot Involvement

The Dermatology Digest

Food and Drug Administration (FDA) has updated the label for dupilumab (Dupixent, Regeneron Pharmaceuticals, Inc. and Sanofi), adding efficacy and safety data for people aged 12 years and older with atopic dermatitis (AD) and uncontrolled moderate-to-severe hand and/or foot involvement. and Sanofi report. “We

article thumbnail

Weighing Risks Vs. Benefits of Systemic AD Treatments

The Dermatology Digest

Shared-decision making focused on weighing risks versus benefits is key when choosing the most appropriate systemic atopic dermatitis (AD) treatment for a patient, according to new research presented at the 2024 American Academy of Allergy, Asthma & Immunology (AAAAI) Annual Meeting in Washington, DC.

article thumbnail

Oh, The Places Dermatology Will Go in 2024!

The Dermatology Digest

Dupilumab (Dupixent, Regeneron Pharmaceuticals, Inc., New systemic agents and even new concepts in the prevention of atopic dermatitis and the microbiome seem just around the corner too, Dr. Lio says. “We Food and Drug Administration (FDA) recently OKed a label update for dupilumab (Dupixent, Regeneron Pharmaceuticals, Inc.,

article thumbnail

Breaking News: Japan First in the World to Approve Dupilumab for CSU

The Dermatology Digest

The Ministry of Health, Labor and Welfare (MHLW) in Japan has granted marketing and manufacturing authorization for dupilumab (Dupixent, Sanofi and Regeneron Pharmaceuticals, Inc.) and Novartis Pharmaceuticals). Japan is the first country to approve dupilumab for CSU. This study met the primary and all key secondary endpoints.

article thumbnail

There’s Something About Eblasakimab: Aslan, Zenyaku Partner to Investigate How it Differs From Other Biologics for AD

The Dermatology Digest

Aslan and Zenyaku are teaming up to explore how eblasakimab’s mechanism of action differs from that of other biologic therapies for atopic dermatitis (AD).